Polyvalent Rev Decoys Act as Artificial Rev-Responsive Elements

AUTOR(ES)

Symensma, Tonia L.

FONTE

American Society for Microbiology

RESUMO

Interactions between Rev and the Rev-responsive element (RRE) control the order, rate, and extent of gene expression in human immunodeficiency virus type 1. Rev decoys may therefore prove to be useful RNA therapeutics for the treatment of AIDS. To improve upon the current generation of Rev decoys that bind single Rev molecules, it would be useful to generate polyvalent Rev decoys that could bind multiple Rev molecules. J. Kjems and P. A. Sharp (J. Virol. 67:4769–4776, 1993) originally constructed functional polyvalent Rev decoys, but the structural context of these polyvalent decoys remains unclear, and it has been argued that the individual decoys were either structurally discrete (Kjems and Sharp, J. Virol. 67:4769–4776, 1993) or were part of an extended helix (R. W. Zemmel et al., Mol. Biol. 258:763–777, 1996). To resolve the differences between these models, we have designed and synthesized concatemers of Rev-binding elements (RBEs) that fold to form multiple, discrete, high-affinity Rev-binding sites. We find that the concatenated RBEs can facilitate the cytoplasmic transport of viral mRNAs and therefore likely bind multiple Rev molecules. These artificial RREs may simultaneously sequester Rev and hinder access to the cellular transport machinery.

Documentos Relacionados

• Identification of the Rev transactivation and Rev-responsive elements of feline immunodeficiency virus.
• Human immunodeficiency virus type 1 Rev-responsive element RNA binds to host cell-specific proteins.
• Human Immunodeficiency Virus Rev Protein Recognizes a Target Sequence in Rev-Responsive Element RNA within the Context of RNA Secondary Structure
• Human immunodeficiency virus rev protein recognizes a target sequence in rev-responsive element RNA within the context of RNA secondary structure.
• Different sites of interaction for Rev, Tev, and Rex proteins within the Rev-responsive element of human immunodeficiency virus type 1.